APA (7th ed.) Citation

S, S., S, S., A, E., M, L., GG, B., M, G., . . . H, O. (2010). Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 5(2), 231. https://doi.org/10.1007/s11481-009-9175-1

Chicago Style (17th ed.) Citation

S, Sinha, et al. "Recombinant TCR Ligand Reverses Clinical Signs and CNS Damage of EAE Induced by Recombinant Human MOG." Journal of Neuroimmune Pharmacology : The Official Journal of the Society on NeuroImmune Pharmacology 5, no. 2 (2010): 231. https://doi.org/10.1007/s11481-009-9175-1.

MLA (9th ed.) Citation

S, Sinha, et al. "Recombinant TCR Ligand Reverses Clinical Signs and CNS Damage of EAE Induced by Recombinant Human MOG." Journal of Neuroimmune Pharmacology : The Official Journal of the Society on NeuroImmune Pharmacology, vol. 5, no. 2, 2010, p. 231, https://doi.org/10.1007/s11481-009-9175-1.